Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.

Usha L, Sill MW, Darcy KM, Benbrook DM, Hurteau JA, Michelin DP, Mannel RS, Hanjani P, De Geest K, Godwin AK.

Gynecol Oncol. 2011 Jun 1;121(3):455-61. doi: 10.1016/j.ygyno.2011.02.013. Epub 2011 Mar 17.

2.

Phase I safety and pharmacokinetic study of bevacizumab in Chinese patients with advanced cancer.

Wu JY, Wu XN, Ding L, Zhao YB, Ai B, Li Y, Hu X, Cheng G.

Chin Med J (Engl). 2010 Apr 5;123(7):901-6.

PMID:
20497685
3.

Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer.

Hanauske AR, Lahn M, Musib LC, Weigang-Köhler K, Yilmaz E, Graefe T, Kuenen B, Thornton D, McNealy P, Giaccone G.

Ann Oncol. 2009 Sep;20(9):1565-75. doi: 10.1093/annonc/mdp049. Epub 2009 Jun 1.

PMID:
19487488
4.

A phase I trial of enzastaurin in patients with recurrent gliomas.

Kreisl TN, Kim L, Moore K, Duic P, Kotliarova S, Walling J, Musib L, Thornton D, Albert PS, Fine HA.

Clin Cancer Res. 2009 May 15;15(10):3617-23. doi: 10.1158/1078-0432.CCR-08-3071. Epub 2009 May 5.

5.

A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors.

Camidge DR, Gail Eckhardt S, Gore L, O'Bryant CL, Leong S, Basche M, Holden SN, Musib L, Baldwin J, Darstein C, Thornton D, Finn RS, Britten CD.

Anticancer Drugs. 2008 Jan;19(1):77-84.

PMID:
18043132
6.

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W.

J Clin Oncol. 2007 Nov 20;25(33):5180-6. Erratum in: J Clin Oncol. 2008 Apr 1;26(10):1773.

PMID:
18024865
7.

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.

Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI.

J Clin Oncol. 2007 Nov 20;25(33):5165-71. Erratum in: J Clin Oncol. 2014 Nov 10;32(32):3686.

PMID:
18024863
8.

Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.

Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R, Vermaat JS, Witteveen EO, Visseren-Grul CM, Musib L, Enas N, van Hal G, Beijnen JH, Schellens JH, Voest EE.

Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4474-81.

9.

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

Shih T, Lindley C.

Clin Ther. 2006 Nov;28(11):1779-802. Review.

PMID:
17212999
10.

Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.

Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, Cole P, Sullivan R, Riddle J, Schmidt J, Enas N, Sinha V, Thornton DE, Herbst RS.

J Clin Oncol. 2006 Sep 1;24(25):4092-9.

PMID:
16943527
11.

Managing patients treated with bevacizumab combination therapy.

Gordon MS, Cunningham D.

Oncology. 2005;69 Suppl 3:25-33. Epub 2005 Nov 21. Review.

PMID:
16301833
12.

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts.

Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, Banks C, Capen A, Goode R, Lewis JE, Sams L, Huss KL, Campbell RM, Iversen PW, Neubauer BL, Brown TJ, Musib L, Geeganage S, Thornton D.

Cancer Res. 2005 Aug 15;65(16):7462-9.

13.

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.

Ferrara N, Hillan KJ, Gerber HP, Novotny W.

Nat Rev Drug Discov. 2004 May;3(5):391-400. Review. No abstract available.

PMID:
15136787
14.

LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice.

Keyes KA, Mann L, Sherman M, Galbreath E, Schirtzinger L, Ballard D, Chen YF, Iversen P, Teicher BA.

Cancer Chemother Pharmacol. 2004 Feb;53(2):133-40. Epub 2003 Oct 31.

PMID:
14593497
15.

Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.

Liang J, Slingerland JM.

Cell Cycle. 2003 Jul-Aug;2(4):339-45. Review.

PMID:
12851486
16.

Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta.

Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A, Mohr M.

Bioorg Med Chem Lett. 2003 Jun 2;13(11):1857-9.

PMID:
12749884
17.

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D.

J Clin Oncol. 2001 Feb 1;19(3):843-50.

PMID:
11157038
18.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG.

J Natl Cancer Inst. 2000 Feb 2;92(3):205-16.

PMID:
10655437

Supplemental Content

Support Center